Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 16/20 | 0.47 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.43 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7343445 | 0.90 | GPR132 (0.52) | GPR132CMKLR2CMKLR1CTSLCTSB | |
| SCHEMBL7835677 | 0.88 | GPR132 (0.42) | GPR132CMKLR2CMKLR1 | |
| SCHEMBL7832625 | 0.84 | TP53 (0.41) | GPR132CMKLR2CMKLR1 | |
| SCHEMBL9392937 | 0.79 | GPR132 (0.42) | GPR132CMKLR2CMKLR1 | |
| SCHEMBL7825812 | 0.79 | TP53 (0.39) | GPR132CMKLR2CMKLR1CTSLCTSB | |
| SCHEMBL6777410 | 0.78 | SUCNR1 (0.54) | GPR132 | |
| SCHEMBL7825718 | 0.77 | TP53 (0.47) | — | |
| SCHEMBL6776672 | 0.76 | GPR132 (0.52) | GPR132CMKLR2CMKLR1 | |
| SCHEMBL7380053 | 0.76 | MEN1 (0.48) | CTSL | |
| SCHEMBL7378476 | 0.75 | ITGB3 (0.54) | CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | disclosed |
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |